TEXAS CAPITAL BANCSHARES INC/TX
Datakwaliteit: 83%
TCBIO
NASDAQ
Financial Services
Depository Institutions
€ 21,70
▼
€ 0,08
(-0,37%)
Marktkapitalisatie: 1,00 B
Prijs
€ 21,78
Marktkapitalisatie
1,00 B
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Earnings grew 326,08% over the past year
Debt/Equity of 0,17 — conservative balance sheet
Generating 347,59 M in free cash flow
P/E of 3,04 — trading at a low valuation
PEG of 0,45 suggests growth is underpriced
Cash machine — converts 105,25% of earnings into free cash flow
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)326,08%
FCF Growth (3Y)-1,38%
Kwaliteit
Return on Equity
9,24%
Boven sectorgemiddelde (9,22%)
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
0,17
Onder sectorgemiddelde (0,49)
Current RatioN/A
Interest CoverageN/A
Waardering
PE (TTM)
3,04
Onder sectorgemiddelde (11,13)
P/B Ratio0,28
EV/EBITDAN/A
Dividend Yield6,59%
Koershistorie
Financiële Trends
Sectorvergelijking
vs Financial Services sector mediaan (2698 peers)
Sectorvergelijking
vs Financial Services sector mediaan (2698 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 3,0 | 11,1 |
| P/B | 0,3 | 1,2 |
| ROE % | 9,2 | 9,2 |
| Net Margin % | — | 9,4 |
| Rev Growth 5Y % | — | 5,8 |
| D/E | 0,2 | 0,5 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 | — | 1,45 B | — |
| FY2026 | — | 1,35 B | — |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 | — | 333,56 M | — |
| 2026 Q1 | — | 318,64 M | — |
Dividend History
Yield
6,59%
Payout Ratio
21,15%
Growth (3Y)
0,00%
Growth (5Y)
N/A
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 02, 2026 | — | € 0,36 | N/A |
| Dec 01, 2025 | — | € 0,36 | N/A |
| Sep 02, 2025 | — | € 0,36 | N/A |
| Jun 02, 2025 | — | € 0,36 | N/A |
| Mar 03, 2025 | — | € 0,36 | N/A |
| Dec 02, 2024 | — | € 0,36 | N/A |
| Sep 03, 2024 | — | € 0,36 | N/A |
| Jun 03, 2024 | — | € 0,36 | N/A |
| Feb 29, 2024 | — | € 0,36 | N/A |
| Nov 30, 2023 | — | € 0,36 | N/A |
| Aug 31, 2023 | — | € 0,36 | N/A |
| May 31, 2023 | — | € 0,36 | N/A |
| Feb 28, 2023 | — | € 0,36 | N/A |
| Nov 30, 2022 | — | € 0,36 | N/A |
| Aug 31, 2022 | — | € 0,36 | N/A |
| May 31, 2022 | — | € 0,36 | N/A |
| Feb 28, 2022 | — | € 0,36 | N/A |
| Nov 30, 2021 | — | € 0,36 | N/A |
| Aug 31, 2021 | — | € 0,36 | N/A |
| May 28, 2021 | — | € 0,36 | N/A |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | 326,08% | Earnings Growth (3Y) | 32,14% |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | 6,79% |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | 330,24 M |
| ROE | 9,24% | ROA | 1,02% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | 347,59 M |
| ROIC | N/A | FCF Growth (3Y) | -1,38% |
| Safety | |||
| Debt / Equity | 0,17 | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 3,64 B |
| Dividends | |||
| Dividend Yield | 6,59% | Payout Ratio | 21,15% |
| Dividend Growth (3Y) | 0,00% | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | 5 yrs | ||
| Valuation | |||
| P/E Ratio | 3,04 | Forward P/E | N/A |
| P/B Ratio | 0,28 | P/S Ratio | N/A |
| PEG Ratio | 0,45 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,69 | Fwd Earnings Yield | N/A |
| FCF Yield | 34,60% | ||
| Market Cap | 1,00 B | Enterprise Value | 1,63 B |
| Per Share | |||
| EPS (Diluted TTM) | 6,79 | Revenue / Share | N/A |
| FCF / Share | 7,54 | OCF / Share | 7,81 |
| EPS CAGR (1Y) | 430,47% | EPS CAGR (5Y) | 10,22% |
| EPS CAGR (10Y) | 9,06% | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 105,25% |
| SBC-Adj. FCF | 312,52 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | 330,24 M | 77,51 M | 189,14 M | 332,48 M | 253,94 M |
| EPS (Diluted) | 6,79 | 1,28 | 3,54 | 6,18 | 4,60 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 52,17 M | 54,23 M | 40,47 M | 45,28 M | 93,41 M |
| Interest Expense | 1,03 B | 901,30 M | 715,80 M | 268,48 M | 107,75 M |
| Income Tax | 102,47 M | 29,55 M | 57,45 M | 99,28 M | 84,12 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 31,54 B | 30,73 B | 28,36 B | 28,41 B | 34,73 B |
| Total Liabilities | 27,91 B | 27,36 B | 25,16 B | 25,36 B | 31,52 B |
| Shareholders' Equity | 3,63 B | 3,37 B | 3,20 B | 3,06 B | 3,21 B |
| Total Debt | 620,58 M | 660,35 M | 859,15 M | 931,44 M | 928,74 M |
| Cash & Equivalents | — | — | — | — | — |
| Current Assets | — | — | — | — | — |
| Current Liabilities | — | — | — | — | — |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
High Yield Value
Apr 12, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Apr 12, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Apr 12, 2026
{"event":"ticker_viewed","properties":{"ticker":"TCBIO","listing_kind":"stock","pathname":"/stocks/tcbio","exchange":"NASDAQ","country":"US"}}